Synonyms: CTX-712 | CTX712
Compound class:
Synthetic organic
Comment: The chemical structure for rogocekib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a dual specificity protein kinase CLK (CDC2-like kinase) inhibitor with proposed antineoplastic action. A structure match via PubChem identified the clinical research code CTX-712 (Chordia Therapeutics). CTX-712 is an orally available, potent CLK inhibitor.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|